Page 2 - Glenmark Pharmaceuticals Ltd News

Glenmark Pharma up 3% on DCGI nod to start phase 3 trial of Envafolimab

Around 11:20 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 3.05 per cent at ₹2,051.40 per share. In comparison, BSE Sensex was trading 0.25 per cent lower at 80,518.51 levels.

These three stocks are a must-have in your portfolio; top reasons here

Markets edged higher and gained over half a percent, supported by optimism surrounding the GST Council meeting.

Don't miss out on these 2 stocks, say analysts at MOFSL; details inside

Recently Nykaa stock had given a breakout on the weekly charts with high volumes. In last few days the stock gradually moved higher and showed relative strength when the markets were correcting.

Glenmark Pharma falls 5% in 2 days on Q1 show; Here's what analysts suggest

Glenmark Pharma stock has tanked over 5 per cent after the company reported lower-than-expected performance in the June 2025 quarter, missing market estimates

Glenmark Pharma Q1 results: Profit falls 86% to ₹47 cr, revenue down 5%

Gelnmark's India revenue stood at ₹1,239.9 crore, up 3.7 per cent Y-o-Y from ₹1,196.2 crore, driven by growth in cardiac, respiratory, and dermatology segments despite weakness in diabetes portfolio

Glenmark Q1 profit tanks 86% on US settlement hit; revenue stays flat

The sharp profit fall was due to a provision of $37.75 million made by Glenmark to settle US antitrust and consumer protection lawsuit with a putative direct purchaser class, subject to court approval

Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why

Pharma stocks fell after Trump said tariffs will be imposed within a week, rising up to 250 per cent in 12-18 months